Trials / Recruiting
RecruitingNCT06724848
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population
A Translational Study in Patients With COPD and Early COPD to Describe Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 850 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory/immunological mechanisms on early COPD, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants initially for 1-year period. The follow-up period may extend up to 3 years depending upon emerging data and feasibility assessment by the sponsor.
Conditions
Timeline
- Start date
- 2024-06-05
- Primary completion
- 2027-10-21
- Completion
- 2027-10-21
- First posted
- 2024-12-09
- Last updated
- 2026-03-27
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06724848. Inclusion in this directory is not an endorsement.